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This quasi-experimental study investigated the effect of an 
antibiotic cycling policy based on time-series analysis of epi-
demiologic data, which identified antimicrobial drugs and time 
periods for restriction. Cyclical restrictions of amoxicillin/clavu-
lanic acid, piperacillin/tazobactam, and clarithromycin were un-
dertaken over a 2-year period in the intervention hospital. We 
used segmented regression analysis to compare the effect on 
the incidence of healthcare-associated Clostridioides difficile 
infection (HA-CDI), healthcare-associated methicillin-resistant 
Staphylococcus aureus (HA-MRSA), and new extended-spec-
trum β-lactamase (ESBL) isolates and on changes in resis-
tance patterns of the HA-MRSA and ESBL organisms between 
the intervention and control hospitals. HA-CDI incidence did 
not change. HA-MRSA incidence increased significantly in 
the intervention hospital. The resistance of new ESBL isolates 
to amoxicillin/clavulanic acid and piperacillin/tazobactam de-
creased significantly in the intervention hospital; however, re-
sistance to piperacillin/tazobactam increased after a return to 
the standard policy. The results question the value of antibiotic 
cycling to antibiotic stewardship.
Restrictive antimicrobial prescribing guidelines have successfully reduced the incidence of Clostridioides 
difficile infection (CDI; formerly Clostridium difficile) and 
methicillin-resistant Staphylococcus aureus (MRSA) (1–
6). However, these guidelines have been suggested to cre-
ate an environment of antimicrobial homogeneity that may 
enhance the development and spread of antimicrobial resis-
tance (7,8). Antibiotic cycling has been proposed as an ef-
fective strategy to increase antimicrobial heterogeneity and 
decrease the development of antimicrobial resistance (8,9). 
This method of increasing antimicrobial heterogeneity has 
had mixed effects on antimicrobial resistance; however, 
investigations have been conducted mainly in intensive 
care units (ICUs) and in patients with specific infections 
(neutropenic sepsis, ventilator-associated pneumonia), and 
cycling periods have been arbitrarily defined, ranging from 
1 week to 6 months (10–22). In a meta-analysis of studies 
investigating antibiotic cycling, the optimal cycling period 
was identified as 30 days (23). When the cycling period is 
too long, the effect becomes equivalent to continuous use 
of a single agent, increasing antimicrobial homogeneity.
We aimed to evaluate the effect of an antibiotic cycling 
policy, derived using time-series analysis of retrospective 
epidemiologic data, on the incidence of healthcare-associ-
ated MRSA (HA-MRSA) and healthcare-associated CDI 
(HA-CDI). A secondary aim was to evaluate the effect of 
this policy on the incidence of infections caused by extend-
ed-spectrum β-lactamase (ESBL)–producing organisms.
Methods
We conducted the main intervention involving antibiotic 
cycling in Antrim Area Hospital (AAH), a 447-bed district 
general teaching hospital in Northern Ireland. Comparative 
data were collected in Causeway Hospital (CH), a 213-bed 
district general teaching hospital in Northern Ireland. Both 
hospitals form part of the Northern Health and Social Care 
Trust (NHSCT), which serves 436,000 persons. AAH and CH 
contain general medical, surgical, maternity, and gynecology 
wards and ICU departments (AAH ICU, 8 beds; CH ICU, 6 
beds). AAH also contains a pediatric ward, a neonatal ICU, and 
a hematology/oncology ward and provides outpatient chemo-
therapy and renal dialysis services. Other specialist services, 
such as burn and transplant units, are provided on a regional 
basis by a neighboring trust. The Office of Research Ethics 
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Study Design
The study comprised 3 phases. First was development of an 
antibiotic cycling policy using retrospective data for April 
2007–March 2012; second, implementation and assess-
ment of the effect of this policy in AAH and comparative 
data collected in CH, where the policy was not implement-
ed; and third, postintervention follow-up after return to the 
standard antibiotic policy in AAH (Table 1; Figures 1, 2).
Data Collection
For the retrospective part of the study (Figure 1), we de-
termined monthly incidence of the output variables (HA-
MRSA, HA-CDI) and input variables (other MRSA; 
other CDI; antimicrobial and infection control agent use; 
pharmacy, medical, and nursing staffing levels [full-time 
equivalents (FTEs), where 1 FTE equals 1 full-time work-
er]; and age-adjusted Charlson comorbidity index of all 
patients discharged from AAH). We obtained a record of 
all MRSA-positive patients identified in AAH from the 
hospital microbiology laboratory. Cases were classified 
as HA-MRSA or other MRSA (Table 1). MRSA isolates 
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Table 1. Overview of a study on the effects of an antibiotic drug cycling policy on the incidence of HA-MRSA and HA-CDI in 2 
hospitals according to the Orion Statement, Northern Ireland, UK* 
Variable Definition 
Population characteristics The NHSCT is 1 of 5 Health and Social Care Trusts in Northern Ireland, serving 436,000 persons. 
The NHSCT has 2 acute care hospitals: AAH (intervention hospital), containing 447 beds, and CH 
(control hospital) containing 213 beds. These hospitals provide acute medical, surgical ICU, 
neonatal, pediatric, and maternity services for the NHSCT. Study wards comprised all adult 
inpatient wards; ICU, NNU, pediatric, and palliative care wards were excluded. 
Retrospective study, 2007 Apr–
2012 Mar 
The intervention design was as follows: An antibiotic cycling policy was devised based on results of 
an analysis of HA-CDI and HA-MRSA incidence in AAH during April 2007–March 2012. This 
analysis identified macrolides and TZP as significantly associated with HA-MRSA with lag times of 
1 mo. AMC was identified as significantly associated with HA-CDI with a lag time of 2 mo. 
Consequently, an antibiotic cycling policy was implemented in AAH that restricted the use of TZP 
and macrolides in alternate months, and AMC was restricted for 2 consecutive months in every 4 
months over a 2-year period. 
Comparison of effect of antibiotic 
cycling policy between AAH and 
CH, 2011 Nov–2016 Sep† 
Comparison of outcome measures before and after the introduction of an antibiotic cycling policy in 
AAH and between the intervention hospital (AAH) and control hospital (CH). Reintroduction of 
standard antibiotic policy in AAH during October 2015–September 2016 to determine whether any 
effect observed during the intervention period was reversed upon return of the standard policy. 
Comparison of outcome measures between intervention and postintervention periods occurred for 
AAH only. 
General infection control 
measures 
Chlorine dioxide 275 ppm was used for routine environmental decontamination through the study 
period in both hospitals. Monthly environmental cleanliness audits were conducted on all wards. 
Throughout the intervention period, infection control practices did not change. 
Isolation and elimination policy All patients in whom CDI was diagnosed were placed in an isolation room. Patients identified as 
colonized or infected with MRSA were placed in an isolation room when one was available. 
However, in the event of a shortage of these rooms, these patients were placed in cohort bays. 
MRSA admission screening In both hospitals all patients with a history of MRSA; admitted from a residential or nursing home; 
admitted from another hospital; admitted to the ICU, NNU, or renal unit; and oncology patients 
were screened. 
Antibiotic stewardship activities After a CDI outbreak in 2008, restrictions were put in place throughout the NHSCT regarding use 
of fluoroquinolones, cephalosporins, clindamycin, and carbapenems (4). All requests for restricted 
antibiotic drugs are reviewed by the antimicrobial pharmacists and consultant microbiologists. 
Weekly audits were conducted on adherence to empirical antibiotic guidelines on all wards. 
Definitions 1.  HA-CDI incidence: No. patients presenting with CDI >48 h after admission to AAH or CH or 
any patient presenting with CDI <48 h after admission to these hospitals who had an 
admission to the same hospital in the preceding 4 wks (24). 
 2.  Other CDI incidence: No. patients presenting with CDI <48 h from admission with no 
admission to AAH or CH in the preceding 4 wks. 
 3.  HA-MRSA incidence: No. patients who tested negative or were not screened for MRSA on 
admission but tested positive for MRSA >48 h after admission (24). Each patient was counted 
once per admission. 
 4.  Other MRSA incidence: No. patients who tested positive for MRSA <48 h after admission. 
 5.  New ESBL incidence: No. newly identified patients from whom an ESBL-producing organism 
was isolated or known patients from whom a new ESBL strain was isolated. Each patient was 
counted once per admission 
 6.  Resistant patterns (MRSA and ESBL): No. isolates per month. Duplicate isolates identified 
within 7 d were excluded. 
*Based on (25). AAH, Antrim Area Hospital; AMC, amoxicillin/clavulanic acid; CDI, Clostridioides difficile infection; CH, Causeway Hospital; ESBL, 
extended-spectrum β-lactamase; HA, healthcare-associated; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; NHSCT, 
Northern Health and Social Care Trust; NNU, neonatal unit; TZP, piperacillin/tazobactam. 
†Preintervention period, 2011 Nov–2013 Sep; intervention period, 2013 Oct–2015 Sep; postintervention period, 2015 Oct–2016 Sep. 
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from clinical samples and screening swab samples were 
detected according to routine microbiological proce-
dures (26). Throughout the study period, targeted MRSA 
screening was undertaken on admission to AAH or CH 
for oncology patients; patients with a history of MRSA; 
patients admitted from a residential or nursing home; and 
patients admitted to the ICU, neonatal unit, or renal unit. 
For each patient, repeat isolates during the same admis-
sion period were excluded.
We obtained data on the number of patients in whom 
CDI was diagnosed from the microbiology laboratory 
and identified HA-CDI and other CDI cases (Table 1). 
During March 2007–April 2009, we identified C. diffi-
cile through detection of toxins A and B from the feces 
of patients with diarrhea using the PremierToxin A and 
B kit (Meridian Bioscience, Europe, http://www.me-
ridianbioscience.eu) and an ELISA technique. In May 
2009, this identification process was changed to a 3-step 
technique using the Techlab C.diff Quik Chek complete 
(Abbott, https://www.alere.com) combined glutamate de-
hydrogenase and toxin A and B enzyme immunoassay and 
the Cepheid Xpert C.difficile PCR (http://www.cepheid.
com) for detection of potentially toxigenic strains (27).
We obtained records of monthly systemic antimicro-
bial drug use from the pharmacy computer system and 
converted to defined daily doses (DDD) (26,28). The use 
of antiseptic agents, such as chlorhexidine skin wash (li-
ters), alcohol-impregnated wipes (number of wipes), and 
alcohol-based hand rub (liters), acted as a proxy measure 
for hand hygiene in the study hospitals (29). We deter-
mined monthly use of these agents across both hospitals 
during the study period from the pharmacy computer sys-
tem and the National Health Service Supply Chain. We 
obtained the monthly number of nursing, auxiliary nurs-
ing, clinical pharmacy, and medical FTEs in AAH from 
the NHSCT Finance Department. We determined the 
monthly average age-adjusted comorbidity for AAH by 
calculating the Charlson age-adjusted comorbidity index 
of all patients discharged each month (30). For all of these 
variables, we adjusted the value to an incidence or use per 
100 occupied bed days (OBD).
Using linear regression, we determined the trends in each 
of the explanatory variables. We constructed autoregressive 
integrated moving average models to model the relationship 
between the input and output variables in AAH for April 
2007–March 2012 (Appendix, https://wwwnc.cdc.gov/EID/ 
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Figure 1. Investigation of the 
effects of an antibiotic drug cycling 
policy on the incidence of HA-
MRSA and HA-CDI in 2 hospitals, 
Northern Ireland, UK. ARIMA, 
autoregressive integrated moving 
average; HA-CDI, healthcare-
associated Clostridioides difficile 
infection; HA-MRSA, healthcare-
associated methicillin-resistant 
Staphylococcus aureus; FTE,  
full-time equivalent.
Figure 2. Antibiotic cycling 
schedule in Antrim Area 
Hospital, Northern Ireland, UK, 
showing the months where each 
antibiotic was recommended. 
Restrictions in the use of each 
antibiotic were in place during 
all other times. AMC, amoxicillin/
clavulanic acid; TZP, piperacillin/
tazobactam.
Effects of Antibiotic Drug Cycling
article/25/1/18-0111-App1.pdf). Based on the antimicrobial 
drugs that were significantly associated with HA-CDI and 
HA-MRSA, together with the time lag between observing 
a change in the antimicrobial drug use and a corresponding 
change in HA-MRSA or HA-CDI incidence, we developed 
an antibiotic cycling policy and implemented it in AAH over 
a 2-year period (October 13–September 15) (Figure 2).
Implementation of Cycling Policy
The antibiotic cycling policy was implemented on wards 
in AAH except pediatrics, neonatal unit, palliative care 
ward, and ICU. We excluded the palliative care ward 
and ICU because patients in these departments usually 
have received multiple previous courses of antimicro-
bial drugs; therefore, empirical guidelines do not apply, 
and antimicrobial therapy is guided by advice from the 
NHSCT Consultant Microbiologists. The cycling policy 
affected the antimicrobial recommendations for commu-
nity-acquired pneumonia, hospital-acquired pneumonia, 
intraabdominal sepsis, and urinary tract infections. In 
months during which all 3 antimicrobial drugs (amoxi-
cillin/clavulanic acid [AMC], piperacillin/tazobactam 
[TZP], and macrolides) were restricted, levofloxacin was 
recommended for the treatment of severe community-ac-
quired pneumonia and intraabdominal sepsis. However, 
levofloxacin could be supplied only on receipt of an or-
der form signed by medical staff. All patients prescribed 
levofloxacin were followed up for 12 weeks. During this 
time, the NHSCT laboratory system was used to deter-
mine the proportion of patients from whom C. difficile 
was isolated from fecal samples or MRSA from screen-
ing swab samples and clinical samples. We constructed 
life tables to determine the probability of remaining CDI- 
and MRSA-free for each week after levofloxacin treat-
ment. After this, the cumulative probability of remaining 
CDI- or MRSA-free was determined and expressed as 
a percentage.
Before implementation of this policy, clinical staff were 
trained on the intervention. Monthly reminders about the 
policy changes were sent to staff groups, and each month a 
new antibiotic policy was displayed on participating wards.
During periods of restriction of a cycled antimicrobial 
drug, stock was removed from all bulk orders, and these 
drugs could be supplied only on receipt of a request form 
signed by a clinician, outlining the patient’s details and 
indication for treatment. During this time, the Trustwide 
antibiotic stewardship activities continued as usual. These 
included review of requests of all restricted antimicrobial 
drugs by the pharmacist and consultant microbiologist and 
weekly audits on adherence to the Trust antibiotic policy. 
Where inappropriate use was identified, it was fed back to 
the prescriber in real time and monthly to all consultants 
and the medical director.
For the preintervention (November 11–September 13), 
intervention (October 13–September 15), and postinterven-
tion (October 15–September 2016) periods in AAH, the in-
cidence of HA-CDI, other CDI, HA-MRSA, other MRSA, 
and the use of antimicrobial drugs and infection control 
agents were collected as described. Furthermore, HA-
MRSA resistance patterns and new ESBL incidence and 
resistance patterns were determined. These variables were 
also identified in CH (November 2011–September 2015) 
for comparative analysis. For HA-MRSA isolates identi-
fied from clinical samples, we determined the percentage 
change in ciprofloxacin, erythromycin, AMC, and TZP re-
sistance during the preintervention and intervention peri-
ods for both hospitals. Duplicate isolates identified within 
7 days of the initial isolate were excluded.
We identified ESBL isolates from clinical samples us-
ing the method described by the European Committee on 
Antimicrobial Sensitivity Testing for the detection of ES-
BLs (31). The monthly number of new ESBL isolates and 
percentage change in gentamicin, ciprofloxacin, AMC, and 
TZP resistance during the preintervention and intervention 
periods was determined for both hospitals.
We assessed the effect of the antibiotic cycling poli-
cy on HA-MRSA, HA-CDI, and new ESBL incidence in 
AAH using segmented regression analysis (32). Segmented 
regression analysis was used to identify changes in the out-
come measures in CH during the study period. We exam-
ined the effect of the antibiotic cycling policy on changes 
in HA-MRSA and new ESBL resistance patterns in AAH 
in comparison with CH using χ2 analysis.
For AAH only, we used the aforementioned tech-
niques to determine the effect of reverting to the standard 
antibiotic policy on HA-MRSA, HA-CDI, and new ESBL 
incidence during October 2015–September 2016. We also 
determined changes in resistance patterns of HA-MRSA 
and new ESBL isolates.
For all analyses, we considered p<0.05 to be statisti-
cally significant. All analyses were conducted using Eviews 
8 software (QMS, http://www.eviews.com/home.html) 
and Microsoft Excel version 13 (https://www.microsoft.
com/en-us).
Results
Retrospective Analysis
During April 2007–March 2012, a total of 275 cases of 
HA-CDI (average monthly incidence 0.047 cases/100 
OBD [range 0–0.18 cases/100 OBD]) and 653 cases of HA-
MRSA (average monthly incidence 0.11 cases/100 OBD 
[range 0.03–0.21 cases/100 OBD]) were reported in AAH 
(Appendix Table 1, Figures 1, 2). Temporal variations in 
HA-CDI incidence followed temporal variations in fluoro-
quinolone use (coefficient 0.005, p<0.01), with a 1-month 
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lag time, and AMC use (coefficient 0.0004, p = 0.02; Ap-
pendix Table 2), with a 2-month lag time. We identified 
significant temporal associations between HA-MRSA inci-
dence and fluoroquinolone use (coefficient 0.004, p<0.01), 
with a 3-month lag time; macrolide use (coefficient 0.002, 
p <0.01), with a 1-month lag time; and TZP use (coefficient 
0.010, p<0.01), with a 1-month lag time (Appendix Table 
3). Based on these findings, an antibiotic cycling policy 
was implemented in AAH during October 2013–Septem-
ber 2015 (Figure 2).
Evaluation of Effect of Intervention
During the preintervention period, AMC use increased sig-
nificantly in AAH (coefficient 0.3603, p<0.01) and CH (co-
efficient 0.3848, p = 0.01) (Appendix Table 4). In AAH, we 
observed a significant increase in TZP (coefficient 0.1119, 
p = 0.02), penicillins with extended-spectrum (coefficient 
0.4702, p = 0.02), and first-generation cephalosporins (co-
efficient 0.022, p<0.01) during this period. In addition, a 
borderline significant increase in total antimicrobial drug 
use was evident. During the intervention period in both 
hospitals, no change in the overall use of TZP (AAH coef-
ficient 0.1211, p = 0.25; CH coefficient 0.086, p = 0.16), 
AMC (AAH coefficient 0.1212, p = 0.64; CH coefficient 
0.0056, p = 0.95), and macrolide (AAH coefficient −0.0126, 
p = 0.96; CH coefficient 0.0756, p = 0.5272) was observed. 
Despite this, in AAH, the monthly use of these antimicro-
bial drugs followed the trend that would be expected during 
the use of the antibiotic cycling policy (Figure 3). In AAH, 
during the intervention period, use of β-lactamase–sensi-
tive penicillins (coefficient −0.1171, p<0.01) and carbapen-
ems (coefficient −0.1124, p<0.01) decreased significantly. 
In CH during the intervention period, use of penicillins with 
extended-spectrum (coefficient 0.7081, p<0.01), tetracy-
clines (coefficient 0.3596, p<0.01), and total antimicrobial 
drugs (coefficient 1.5278, p<0.01) increased significantly. 
Use of carbapenems, first-generation cephalosporins, and 
β-lactam–sensitive penicillins also decreased significantly 
(Appendix Table 4).
Throughout the preintervention period, the average 
monthly adherence to the standard antibiotic policy was 
92% in AAH and 91% in CH. HA-CDI and new ESBL 
incidence did not change significantly in either hospi-
tal; however, after the antibiotic cycling policy was in-
troduced in AAH, a significant increasing trend in HA-
MRSA incidence was observed, which was not evident 
in CH (Table 2; Figure 4). A subset analysis of the AAH 
HA-MRSA isolates from clinical samples also demon-
strated a significant increase in the HA-MRSA trend (co-
efficient 0.0023, p<0.01).
During the intervention period, 792 patients received 
levofloxacin; 15 tested MRSA positive before receiving 
levofloxacin and were excluded from the MRSA cohort 
(Appendix Figure 3). Eleven patients tested MRSA posi-
tive during the follow-up period, and 81 patients died. The 
probability of remaining MRSA-free after the 12-week fol-
low-up period was 98.5% (Appendix Figure 4). The CDI 
cohort comprised 792 patients, of whom 87 died during the 
follow-up period. Two patients tested C. difficile glutamate 
dehydrogenase–positive and C. difficile toxin negative, and 
9 patients tested C. difficile toxin positive (Appendix Fig-
ure 5). The probability of remaining free of CDI during the 
12-week follow-up period was 98.5% (Appendix Figure 6).
Evaluation of Postintervention Effect
During the postintervention period, the average monthly ad-
herence to the standard antibiotic policy in AAH remained 
at 92% (Appendix Table 4). The overall trend in the use of 
each of the cycled antimicrobial drugs remained unchanged 
56 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 1, January 2019
Figure 3. Trends in antibiotic use throughout preintervention 
(November 2011–September 2013), intervention (October 2013–
September 2015), and postintervention (October 15–September 
2016) periods in Antrim Area Hospital, Northern Ireland, UK. 
A) amoxicillin/clavulanic acid; B) piperacillin/tazobactam; C) 
macrolides; D) fluoroquinolones. Antibiotic use is defined daily 
doses/100 bed days.
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during the postintervention period (TZP trend coefficient 
0.147, p = 0.12; macrolide trend coefficient −0.1699, p = 
0.55; AMC trend coefficient 0.2996, p = 0.16; fluoroquino-
lone trend coefficient 0.148, p = 0.30). However, in AAH, 
use of monobactams decreased significantly (coefficient 
−0.2382, p<0.01 [Appendix Table 4]). Segmented regres-
sion analysis identified an immediate borderline significant 
decrease in HA-MRSA incidence and an immediate signifi-
cant increase in new ESBL incidence (Table 3). A subset 
analysis of AAH HA-MRSA isolates from clinical samples 
demonstrated no change in the incidence of this organism 
after the end of antibiotic cycling; however, the level of 
HA-MRSA from clinical samples immediately decreased 
significantly (coefficient −0.029, p = 0.0261).
Effect of Antibiotic Cycling on Antimicrobial Resistance
During the preintervention, intervention, and postinterven-
tion periods in AAH and the equivalent periods in CH, 
HA-MRSA resistance to ciprofloxacin and erythromycin 
did not change (Table 4). We observed a significant de-
crease in resistance to AMC (–31.85% change, p<0.01) 
and TZP (–54.79% change, p<0.01) among new ESBL iso-
lates in AAH during the intervention period (Table 5). In 
AAH after reintroduction of the standard antibiotic policy, 
new ESBL resistance to TZP (+11.75% change, p = 0.04), 
gentamicin (+23.5% change, p<0.01), and ciprofloxacin 
(+16.32% change, p<0.01) increased significantly.
Discussion
The use of antibiotic cycling to reduce antimicrobial re-
sistance has been heavily debated, and many studies have 
produced conflicting results (10–22,33). We aimed to imple-
ment an antibiotic cycling policy throughout a hospital where 
the analysis of local epidemiologic data using autoregressive 
integrated moving average modeling provided the framework 
for the antibiotic cycling policy. The cycling of AMC, TZP, 
and macrolides, which the initial retrospective study predicted 
would decrease the incidence of HA-CDI and HA-MRSA, did 
not achieve this objective. HA-CDI incidence did not change 
during the intervention period. In addition, for patients who 
received levofloxacin, the probability of remaining free from 
CDI or MRSA in the 12 weeks after treatment was 98.5%. The 
incidence of new ESBL isolates during the intervention period 
remained unchanged, but resistance of new ESBL isolates to 
TZP and AMC decreased. During the postintervention period, 
when the standard antibiotic policy was in place, resistance of 
ESBL-producing organisms to TZP increased.
During the antibiotic cycling period, the incidence 
of HA-MRSA from clinical and surveillance samples in-
creased significantly in AAH but reversed when the stan-
dard antibiotic policy was reintroduced. Many studies 
have highlighted the increased risk for MRSA infection in 
MRSA carriers. Recent studies reported an increased risk 
for invasive MRSA infection in persistent and intermittent 
MRSA carriage compared with placebo (34–36). The find-
ings in our study are supported by those of a subset analysis 
of HA-MRSA isolates from clinical samples but must be 
interpreted with caution because of the small number of 
clinical samples included in the total HA-MRSA sample.
A recent meta-analysis hypothesized that a 1-month 
cycling period is the optimum time frame to reduce an-
timicrobial resistance (23). In our study, the monthly 
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Table 2. Segmented regression analysis of the incidence of HA-CDI, HA-MRSA, and infections caused by new ESBL isolates in a 
hospital with a cycling policy and a hospital with a standard policy, Northern Ireland, UK* 
Variable 
AAH, cycling policy  CH, standard policy 
Coefficient 95% CI SE p value Coefficient 95% CI SE p value 
HA-CDI          
 Constant 0.0236 0.0099 to 0.0373 0.0068 <0.01  2.9873† 3.669 to 2.3055 0.3378 <0.01 
 Trend 9.34 × 105 0.0009 to 0.0011 0.0005 0.85  0.01905† –0.0603 to 0.0222 0.0204 0.36 
 Change          
  In level 0.0084 0.0270 to 0.0102 0.0092 0.36  0.1335† 0.6324 to 0.3654 0.2472 0.59 
  In trend 0.0004 0.0010 to 0.0017 0.0007 0.58  0.0053† 0.0394 to 0.0500 0.0221 0.81 
HA-MRSA          
 Constant 0.1100 0.0856 to 0.1343 0.0121 <0.01  0.0849 0.0562 to 0.1135 0.01421 <0.01 
 Trend 2.96 × 103 0.0047 to 0.0012 0.0009 <0.01  0.0008 0.0029 to 0.0013 0.0010 0.46 
 Change          
  In level 0.0196 0.0134 to 0.05261 0.01634 0.24  0.0230 0.0158 to 0.0618 0.01925 0.24 
  In trend 0.0041 0.0017–0.0066 0.0012 <0.01  0.0005 0.0034 to 0.0023 0.0014 0.72 
New ESBL          
 Constant 3.7851† 4.3481 to 3.2222 0.2790 <0.01  0.0370 0.0119 to 0.0621 0.0124 <0.01 
 Trend 0.0018† 0.0428 to 0.0393 0.0203 0.93  0.0004 0.0023 to 0.0015 0.0009 0.68 
 Change          
  In level 0.4846† 0.2776 to 1.2469 0.3777 0.21  0.0093 0.0440 to 0.0045 0.0172 0.59 
  In trend 0.0099† 0.0464 to 0.0662 0.0279 0.72  0.0019 0.0006 to 0.1564 0.0013 0.13 
 Outlier at 2013 Jul, 
CH only 
NA NA NA NA  0.0949 0.0333 to 0.1564 0.0305 <0.01 
*Bold indicates statistical significance. AAH, Antrim Area Hospital; CH, Causeway Hospital; CDI, Clostridioides difficile infection; ESBL, extended-
spectrum β-lactamase; HA, healthcare-associated; MRSA, methicillin-resistant Staphylococcus aureus; NA, not applicable.  
†Data logarithmically transformed. 
 
SYNOPSIS
cycling of clarithromycin and TZP did not decrease the 
incidence of HA-MRSA and HA-CDI. The reintroduc-
tion of fluoroquinolones, which are known to be asso-
ciated with CDI and MRSA, may have contributed to 
the increase in HA-MRSA (4,37,38). In CH, fluoroqui-
nolone use (5.86 DDD/100 OBD) was about half that in 
AAH (10.38 DDD/100 OBD), and HA-MRSA incidence 
did not change. Despite increased fluoroquinolone use in 
AAH, HA-CDI incidence did not change during the in-
tervention and postintervention periods, when fluoroqui-
nolone use decreased. Other studies have demonstrated 
decreases in CDI after reductions in AMC, fluoroqui-
nolones, cephalosporin, clindamycin, and amoxicillin 
use (39,40). However, in these studies, the baseline 
incidence of CDI was ≈10-fold higher than in our in-
vestigation (0.2 cases/100 OBD vs. 0.02 cases/100 OBD 
in AAH). Furthermore, fluoroquinolones are particular-
ly associated with C. difficile ribotype 027 (4). During 
an outbreak of this ribotype in AAH, average monthly 
fluoroquinolone use was 13 DDD/100 OBD, which was 
less than the highest levels (23 DDD/100 OBD) during 
the intervention period in our investigation (4). Despite 
these well-documented associations, we observed no 
such increase in HA-CDI during the cycling period. Ver-
naz et al. found no significant association between fluo-
roquinolone use and CDI in a setting where the baseline 
incidence was similar to that in AAH (0.027 cases/100 
OBD) (40). That study suggested that in the nonoutbreak 
situation with an absence of the 027 strain and low base-
line CDI incidence, when coupled with good infection 
control practices, antimicrobial drugs might play a less 
important role in transmitting this organism.
Although the antibiotic cycling policy was not de-
signed to reduce ESBL incidence, we monitored this or-
ganism to ensure it did not increase as an inadvertent effect 
of the intervention, particularly the reintroduction of fluo-
roquinolones. New ESBL incidence did not change during 
the intervention period, but upon return of the standard pol-
icy, new ESBL incidence immediately increased in AAH. 
Because this increase did not continue throughout the pos-
tintervention period, it might have been a delayed effect of 
the antibiotic cycling policy. An association between ESBL 
incidence in AAH and both hospital fluoroquinolone use 
and community AMC use has previously been described; 
therefore, the increase in new ESBL-producing organisms 
in our study might have resulted from the increased use of 
fluoroquinolones during the intervention and postinterven-
tion periods (41). Primary care antimicrobial drug use also 
might have contributed to the increase in ESBL-producing 
organisms, but because we did not measure that variable, 
we cannot quantify the association. 
Previous studies have demonstrated reversal in fluo-
roquinolone resistance after continuous restriction of this 
drug (41). However, our study demonstrated a reduction 
in TZP and AMC resistance after cycling of these agents, 
which was reversed for TZP upon its return to the policy, 
suggesting that through cycling, the balance between us-
ing TZP and reducing resistance can be achieved. Several 
studies have demonstrated the effectiveness of β-lactam/β-
lactamase combinations in treating infections caused by 
ESBL-producing organisms, particularly infections with 
organisms for which the MICs for TZP are <16 µg/L 
(42–45). Harris et al. highlighted the lack of well-designed 
studies proving that β-lactam/β-lactamase combinations 
are inferior to carbapenems in treating these infections and 
called for more robust studies in this area (46). The findings 
of our study may provide a treatment option in less severe 
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Figure 4. Incidence of healthcare-associated methicillin-resistant 
Staphylococcus aureus (A), healthcare-associated Clostridium 
difficile infection (B), and new extended-spectrum β-lactamase (C) 
cases throughout preintervention (November 2011–September 
2013), intervention (October 2013–September 2015), and 
postintervention (October 15–September 2016) periods in Antrim 
Area Hospital and Causeway Hospital, Northern Ireland, UK. 
Black lines, Antrim Area Hospital; gray lines, Causeway Hospital. 
Incidence is number of cases per 100 occupied bed days.
Effects of Antibiotic Drug Cycling
infections caused by ESBL-producing organisms, enabling 
carbapenems to be spared.
The successful implementation of the antibiotic cycling 
policy relied heavily on face-to-face engagement with all hos-
pital staff during its development. We sought feedback from 
each department about potential issues with the proposed re-
strictions. A main difficulty was managing the restriction at 
ward level, ensuring restricted stock could not be unnecessar-
ily prescribed. AAH benefited from the presence of a clinical 
pharmacist and pharmacy technician on all inpatient wards. 
These pharmacists were vital in ensuring that all ward staff 
were aware of the restrictions in a given month. Pharmacy 
technicians removed restricted antimicrobial drugs from the 
ward stock lists so the ward could not order a restricted drug 
without a preorder form outlining the patient’s details and the 
reason for the prescription. This resource-intense intervention 
might be challenging to deliver in other settings, particularly 
where clinical pharmacy resources are limited.
Because this study was ecological in design, it suffers 
from the ecological fallacy, where inferences made at the 
population level cannot be extrapolated to the patient level. 
However, because of the complex dynamics of healthcare-
associated infection transmission, antimicrobial drug use at 
the population level contributes to the individual risk for 
healthcare-associated infections (47). The use of alcohol-
based hand rub and chlorhexidine skin wash was used as 
proxy for infection control practices because obtaining 
consistent data on compliance with isolation and infection 
control policies was not possible. During the intervention 
and postintervention periods, the use of other groups of 
antibiotics in AAH and CH changed significantly because 
controlling the use of all antimicrobial drugs was not pos-
sible. The decrease in monobactam use in AAH during the 
postintervention period resulted from ending the interven-
tion, whereby aztreonam was replaced by the previously 
restricted AMC and TZP.
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Table 3. Segmented regression analysis of effect of stopping cycling on the incidence of HA-CDI, HA-MRSA, and new ESBL isolates 
in Antrim Area Hospital, Northern Ireland, UK* 
Variable Coefficient 95% CI SE p value 
HA-CDI     
 Constant 0.0173 0.0062 to 0.0284 0.0054 <0.01 
 Trend 4.73 × 104 0.0003 to 0.0012 0.0004 0.22 
 Change     
  In level 0.0159 0.0352 to 0.0033 0.0094 0.10 
  In trend 0.0005 0.0018 to 0.0028 0.0011 0.65 
HA-MRSA     
 Constant 0.0598 0.0388 to 0.0810 0.0102 <0.01 
 Trend 0.0012 0.0002 to 0.0027 0.0007 0.10 
 Change     
  In level 0.0350 0.0711 to 0.001 0.0179 0.06 
  In trend 0.0016 0.002 to 0.0027 0.0022 0.45 
New ESBL     
 Constant 0.0438 0.0200 to 0.0672 0.0115 <0.01 
 Trend 0.0005 0.0011 to 0.0021 0.0008 0.56 
 Change     
  In level 0.0419 0.0017 to 0.0820 0.0199 0.04 
  In trend 0.0026 0.0074 to 0.0023 0.0024 0.30 
*In this hospital, a cycling policy was in place during October 2013–September 2015, and a standard policy was in place during October 2015–September 
2016. Bold indicates statistical significance. ESBL, extended-spectrum β-lactamase; HA-CDI, healthcare-associated Clostridioides difficile infection;  
HA-MRSA, healthcare-associated methicillin-resistant Staphylococcus aureus.  
 
 
Table 4. Changes in resistance patterns of healthcare-associated methicillin-resistant Staphylococcus aureus clinical isolates, 
Northern Ireland, UK* 
Antibiotic comparison 
AAH, no. resistant isolates/total tested (%)  CH, no. resistant isolates/total tested (%) 
Preintervention 
resistance 
Intervention 
resistance p value 
Preintervention 
resistance 
Intervention 
resistance p value 
Preintervention vs. intervention        
 Amoxicillin/clavulanic acid 2/2 (100) 2/2 (100) NA  2/2 (100) 0 NA 
 Piperacillin/tazobactam 1/1 (100) 1/1 (100) NA  1/1 (100) 0 NA 
 Ciprofloxacin 66/66 (100) 77/78 (98.7) 0.99  31/31 (100) 33/34 (97.1) 0.17 
 Erythromycin 54/70 (77.1) 69/80 (86.3) 0.18  23/32 (71.9) 22/35 (65.9) 0.43 
Intervention vs. postintervention        
 Amoxicillin/clavulanic acid 2/2 (100) 2/2 (100) NA  NR NR NR 
 Piperacillin/tazobactam 1/1 (100) 0 NA  NR NR NR 
 Ciprofloxacin 77/78 (98.7) 27/27 (100) 0.74  NR NR NR 
 Erythromycin 69/80 (86.3) 23/28 (82.1) 0.40  NR NR NR 
*In AAH (antibiotic cycling policy) and CH (standard antibiotic policy), the preintervention period was November 2011–September 2013, and the 
intervention period was October 2013–September 2015. In AAH, the postintervention period was October 2015–September 2016. AAH, Antrim Area 
Hospital; CH, Causeway Hospital; NA, no isolates tested against amoxicillin/clavulanic acid and piperacillin/tazobactam; NR, data not recorded. 
 
RESEARCH
For analysis of changes in HA-MRSA resistance pat-
terns, we included only clinical samples, which accounted 
for 30% of total MRSA isolates. Before the intervention, 
the trend in new ESBL resistance to AMC and TZP was de-
creasing as a result of a change in interpretative standards 
from Clinical and Laboratory Standards Institute to Euro-
pean Committee on Antimicrobial Susceptibility Testing 
breakpoints in November 2011 (31). Selection and informa-
tion biases were limited in this study through the inclusion 
of all patients with HA-MRSA, HA-CDI, and a new ESBL-
producing organism. All data were collected from electronic 
databases that were populated as part of routine microbiol-
ogy procedures. This study is also limited by the relatively 
short intervention period of 2 years, compared with other 
studies with intervention periods of 5–9 years, which result-
ed in changes in antimicrobial resistance (13,18).
Our results suggest that antibiotic cycling is not an ap-
propriate strategy to reduce the incidence of HA-MRSA or 
HA-CDI but might be effective in reducing ESBL resis-
tance. The increased use of fluoroquinolones in a cyclical 
fashion was not associated with any increase in HA-CDI, 
suggesting that this method may help diversify antimicro-
bial drug use while mitigating adverse effects.
This work was supported by a grant from the Northern Ireland 
Health and Social Care Research and Development Office 
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In 1928, while studying Staphylococcus bacteria at Saint Mary’s Hospital in London, Alexander Fleming noticed that one of his petri dishes was contaminated 
with mold, which was causing the bacteria near it to lyse. Because the mold was 
identified as belonging to the genus Penicillium (Latin for “brush,” referring to the 
chains of conidia that resemble a paintbrush or broom), Fleming named the antibacte-
rial substance penicillin.
Among the earliest known clinical uses of penicillin was by Cecil George Paine, 
a pathologist at the Sheffield Royal Infirmary, who successfully used it in 1930 to treat 
gonococcal conjunctivitis in neonates. Thereafter, the therapeutic potential of penicil-
lin went largely unexplored until 1940, when a team of researchers headed by Howard 
Florey and Ernst Chain showed that it produced dramatic improvements in mice with 
streptococcal infections. Penicillin was instrumental in treating infections in Allied sol-
diers in World War II; however, shortly thereafter, resistance became a substantial 
clinical problem.
Two conidiophores of Penicillium frequentans 
fungi, also known as P. glabrum. The 
conidiophore is the stalked structure whose 
distal end produces asexual spores (conidia) 
by budding. Original magnification x1,200.  
Photo: CDC/Lucille Georg/1971.
